for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AxoGen Inc

AXGN.OQ

Latest Trade

15.61USD

Change

-0.00(-0.00%)

Volume

120,185

Today's Range

15.22

 - 

15.73

52 Week Range

10.99

 - 

35.01

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

AxoGen, Inc. Reports 2019 Third Quarter Financial Results

Nov 6 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. REPORTS 2019 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.07.Q3 LOSS PER SHARE $0.14.Q3 SALES $28.6 MILLION.SEES FY 2019 REVENUE $106 MILLION TO $110 MILLION.SAYS REITERATES ITS 2019 EXPECTATION FOR GROSS MARGIN TO REMAIN ABOVE 80%.

James Flynn Reports 6.29% Passive Stake In Axogen Inc

Aug 19 (Reuters) - AxoGen Inc <AXGN.O>::JAMES FLYNN REPORTS 6.29% PASSIVE STAKE IN AXOGEN INC AS OF AUGUST 7 - SEC FILING.

Axogen Inc Reports Q2 2019 Results

Aug 6 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. REPORTS 2019 SECOND QUARTER FINANCIAL RESULTS.Q2 ADJUSTED LOSS PER SHARE $0.10.Q2 LOSS PER SHARE $0.18.Q2 REVENUE ROSE 30 PERCENT TO $26.7 MILLION.SEES FY 2019 REVENUE ABOUT $106 MILLION TO $110 MILLION.REITERATES ITS EXPECTATION FOR GROSS MARGIN TO REMAIN ABOVE 80% FOR 2019.

Axogen Reports Q1 Loss Per Share $0.24

May 8 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS.Q1 ADJUSTED LOSS PER SHARE $0.15.Q1 LOSS PER SHARE $0.24.Q1 REVENUE ROSE 35 PERCENT TO $23.3 MILLION.SEES FY 2019 REVENUE $109 MILLION TO $114 MILLION.ENDED QUARTER WITH $113.8 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENTS COMPARED TO $122.6 MILLION AT END OF Q4 OF 2018.Q1 EARNINGS PER SHARE VIEW $-0.13, REVENUE VIEW $22.3 MILLION -- REFINITIV IBES DATA.FY2019 REVENUE VIEW $111.4 MILLION -- REFINITIV IBES DATA.

Axogen Says Recon Study Will Support Submission Of Biologic License Application To FDA For Avance Nerve Graft

April 22 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. ANNOUNCES COMPLETION OF PLANNED INTERIM ANALYSIS AND ONE-TIME ENROLLMENT EXPANSION FOR RECON® STUDY.AXOGEN INC - STUDY WILL SUPPORT SUBMISSION OF A BIOLOGIC LICENSE APPLICATION (BLA) TO FDA FOR AVANCE NERVE GRAFT.AXOGEN INC - STUDY ENROLLMENT TARGET WILL BE INCREASED BY 50 SUBJECTS TO A TOTAL TARGET OF 220 SUBJECTS.AXOGEN INC - EXPECTS TO COMPLETE ENROLLMENT DURING SUMMER OF 2020.

Axogen Inc Reports Fourth Quarter Results

Feb 26 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. REPORTS 2018 FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 ADJUSTED LOSS PER SHARE $0.09.Q4 LOSS PER SHARE $0.13.SEES FY 2019 REVENUE $109 MILLION TO $114 MILLION.Q4 REVENUE ROSE 38 PERCENT TO $23.4 MILLION.REITERATES ITS EXPECTATION FOR GROSS MARGIN TO REMAIN ABOVE 80% FOR 2019.

AxoGen Sees FY 2019 Revenue Up At Least 35 Pct

Jan 7 (Reuters) - AxoGen Inc <AXGN.O>::SEES Q4 REVENUE AT LEAST $23.4 MILLION.SEES FY 2019 REVENUE UP AT LEAST 35 PERCENT.SEES FY 2018 REVENUE AT LEAST $83.9 MILLION.Q4 REVENUE ROSE 38 PERCENT TO $23.4 MILLION.COMPANY REAFFIRMS 2019 FINANCIAL GUIDANCE AND PROVIDES BUSINESS UPDATE.FY2018 REVENUE VIEW $84.6 MILLION -- REFINITIV IBES DATA.

Axogen Inc Reiterates Financial Guidance for 2018 and 2019

Nov 19 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN INC - MANAGEMENT REITERATES 2018 ANNUAL REVENUE WILL GROW AT LEAST 40% OVER 2017 REVENUE AND GROSS MARGINS WILL REMAIN ABOVE 80%.AXOGEN INC - MANAGEMENT REITERATES 2019 ANNUAL REVENUE WILL GROW AT LEAST 35% OVER 2018 REVENUE AND GROSS MARGINS WILL REMAIN ABOVE 80%.AXOGEN INC - EXPECTS TO LAUNCH AXOGUARD NERVE CAP IN SECOND HALF OF 2019.

AxoGen Q3 Adjusted Loss Per Share $0.05

Oct 29 (Reuters) - AxoGen Inc <AXGN.O>::AXOGEN, INC. REPORTS 2018 THIRD QUARTER FINANCIAL RESULTS.Q3 ADJUSTED LOSS PER SHARE $0.05.Q3 LOSS PER SHARE $0.11.Q3 REVENUE ROSE 41 PERCENT TO $22.7 MILLION.SEES FY 2018 REVENUE UP AT LEAST 40 PERCENT.SEES FY 2019 REVENUE UP AT LEAST 35 PERCENT.REITERATES FULL YEAR 2018 GUIDANCE AND INTRODUCES 2019 GUIDANCE.

Avance Nerve Graft Receives Regenerative Medicine Advanced Therapy Designation

Oct 29 (Reuters) - AxoGen Inc <AXGN.O>::AVANCE® NERVE GRAFT RECEIVES REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION.AXOGEN - CONTINUES TO ENROLL ITS PIVOTAL STUDY, RECON, UNDER IND PROGRAM AND ANTICIPATES ENROLLMENT TO BE COMPLETE BY END OF 2018.AXOGEN INC - FDA HAS GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION TO AVANCE® NERVE GRAFT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up